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The homeostasis of organs and tissues requires a complex
orchestration of many cell-cell interactions. In addition to provid-
ing specific physiological functions, most tissues exhibit the
capacity for the identification, deletion, and replacement of
damaged cells. As such, within any specific tissue, equilibrium
exists among renewal, differentiation, and cell death. Although
the regulatory mechanisms that govern these states usually
operate highly effectively, disruption of these control points
plays an important role in the genesis of cancer, and may also
contribute to the pathogenesis of aging.
Work from many laboratories has begun to identify and
characterize the molecular interactions that regulate cell sur-
vival, renewal, and differentiation. In some cases, we now pos-
sess significant insight into the connections between specific
molecules and cell behavior. In particular, recent advances in
several fields have enhanced our understanding of the regula-
tion of cell cycle progression, apoptosis, and the many factors
that control proliferative lifespan. However, one theme that also
emerges from these studies is that such regulatory pathways
involve highly interdependent networks of signaling interac-
tions. As a consequence, key checkpoints often control several
possible functional outcomes. Thus, to understand the opera-
tion of these regulatory steps, we must not only identify the
components of these regulatory and effector pathways, but also
further characterize those interactions that modify the functional
outcome of specific signaling pathways.
The study of cancer has provided, and will continue to pro-
vide, important insights into these regulatory pathways. Cancer
cells harbor alterations in key steps that regulate cell prolifera-
tion, differentiation, and cell-cell communication. These muta-
tions endow cancer cells with the phenotypes associated with
the malignant state (Hanahan and Weinberg, 2000). By under-
standing how these genetic alterations affect the function of sig-
naling and regulatory networks, we will begin to understand the
function of these pathways in both normal and malignant cells.
In addition, this knowledge promises to facilitate the rational
design and implementation of molecularly targeted anticancer
therapies.
Recent advances in our understanding of the pathways that
control cell cycle progression, senescence, and apoptosis were
the focus of the Beatson International Cancer Conference
Institute, held June 20–23 in Glasgow, Scotland. The meeting
was again sponsored by Cancer Research UK and the
Association for International Cancer Research and brilliantly
organized by the Beatson Institute for Cancer Research.
Multiple roles for telomeres and telomerase in regulating
chromosomal stability and proliferative lifespan
Telomeres are nucleoprotein structures that cap chromosome
ends. Abundant genetic evidence indicates that these struc-
tures play essential roles in maintaining genomic stability and
that telomere dysfunction leads to genomic instability (Chan
and Blackburn, 2002). Indeed, recent evidence suggests that
dysfunctional telomeres induce some of the same mechanisms
that repair double-strand DNA breaks, suggesting that these
structures normally shield chromosome ends from recognition
as a broken DNA fragment (de Lange, 2002).
In addition to this protective function, the status of telomere
maintenance contributes to the control of replicative lifespan
(Harley et al., 1994). Most normal human cells exhibit telomere
attrition with prolonged passage in culture (Harley et al., 1990;
Hastie et al., 1990) and only transiently express telomerase, the
ribonucleoprotein reverse transcriptase that maintains telomere
structure, at levels insufficient to elongate telomeres (Broccoli
et al., 1995; Masutomi et al., 2003). In contrast, the majority of
human cancers and immortal cell lines express constitutive
telomerase activity and maintain stable telomere lengths with
passage in culture (Kim et al., 1994). Overexpression of the
rate-limiting catalytic subunit of telomerase, hTERT, in mortal
human cells leads to stabilized telomere lengths (Bodnar et al.,
1998; Vaziri and Benchimol, 1998), facilitates immortalization,
and cooperates with other genetic alterations to transform
human cells (Hahn et al., 1999), suggesting that the acquisition
of constitutive telomerase activity contributes directly to the
immortal phenotype and cancer.
However, the role of telomeres and telomere maintenance
in cancer development is complex. One prediction from the
observations described above is that telomere attrition, as is
observed with repeated cell divisions, should serve to suppress
tumor formation. Consistent with these predictions, normal
human cells lacking constitutive telomerase expression never
spontaneously immortalize (Shay and Wright, 1989), and
instead enter an irreversible growth arrest termed replicative
senescence. In addition, mice lacking the RNA subunit of telo-
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merase (mTERC) show a diminished susceptibility to cancer
development induced by chemical carcinogens in a skin papillo-
ma model (Gonzalez-Suarez et al., 2000) or by functional loss
of the INK4A-ARF locus (Greenberg et al., 1999).
However, telomere attrition in mTERC null mice also lacking
the p53 tumor suppressor protein leads to rampant genomic
instability (Chin et al., 1999a) and an increase in tumorigenicity
with characteristic alterations observed in human epithelial can-
cers (Artandi et al., 2000). Moreover, although normal human
cells enter replicative senescence and arrest with passage,
cells harboring inactivating alterations of the p53 and retinoblas-
toma (RB) tumor suppressor pathways divide until they reach a
second proliferative barrier, termed crisis, characterized by
widespread cell death by apoptosis and karyotypic instability
(Shay et al., 1991). The rare cells that survive crisis exhibit sta-
bilized telomere lengths, most often through constitutive activa-
tion of telomerase (Counter et al., 1992). Thus, while these
observations provide a broad framework for understanding the
roles of telomeres and telomerase in cancer development, we
still lack a detailed understanding of how telomere biology con-
tributes to cancer.
In particular, dysfunctional telomeres may trigger several
different effector pathways, including replicative senescence,
apoptosis (crisis), genomic instability, and/or DNA damage
repair, depending upon the context under which telomere
uncapping occurs. One clue to understanding how telomeres
accomplish this signal integration and processing involves spe-
cific protein complexes associated with the telomeric DNA. Titia
de Lange (Rockefeller University, New York) described recent
work from her laboratory concerning the roles of the complex
anchored at the telomere by the telomere binding protein,
TRF2. The TRF2 complex contains several proteins, including
the Mre 11 complex (Zhu et al., 2000), the Werner’s Syndrome
helicase WRN (Opresko et al., 2002), hRap1 (Li et al., 2000),
and the ERCC1/XPF nucleotide excision repair endonuclease
(Zhu et al., 2003). The expression of dominantly interfering
mutants of TRF2 rapidly induces telomere dysfunction and acti-
vates a DNA damage response at telomeres (Takai et al.,
2003), which leads to either senescence or apoptosis in a cell
type-specific manner. Thus, this experimental system permits
one to study the consequences of telomere dysfunction under
carefully controlled conditions. Using this system, Zhu et al.
have shown that the TRF2 complex protects telomeres from
nonhomologous end joining in part by sequestering 3′ telomeric
overhangs from the ERCC1/XPF endonuclease (Zhu et al.,
2003). These observations suggest that this complex plays an
important role in determining the specific consequences of
telomere dysfunction.
While TRF1 and TRF2 bind to double-stranded telomeric
DNA, a third mammalian telomere binding protein, protection of
telomeres 1 (POT1), binds single-stranded telomeric DNA and
also regulates telomere integrity (Baumann and Cech, 2001).
Consistent with studies in fission yeast, Chris Counter (Duke
University, Durham) showed that suppresion of hPOT1 induces
genomic instability and the formation of DNA bridges between
cells after cytokinesis. Joachim Lingner (Swiss Institute for
Experimental Cancer Research, Lausanne) showed that POT1
negatively regulates telomerase activity, and that this function
requires the DNA binding domain of POT1, observations in
agreement with work from the de Lange laboratory (Loayza and
De Lange, 2003). Consistent with these findings, overexpres-
sion of a mutant POT1 lacking the DNA binding domain leads to
telomere elongation. However, Roger Reddel (Children’s
Medical Research Institute, Sydney) and Chris Counter report-
ed that under some conditions, overexpression of full-length
POT1 (Colgin et al., 2003) or a POT1-hTERT fusion protein
(Armbruster et al., 2004) leads to telomere elongation. Since
POT1 is part of a large protein complex that also includes TRF1
(Liu et al., 2004; Ye et al., 2004), these findings suggest that
POT1, through interactions with other proteins, serves to inte-
grate signals regarding telomere status to control telomere
length by regulating telomerase activity at the telomere.
Moreover, these observations reinforce the notion that
telomere maintenance is regulated at several levels. Joachim
Lingner described an assay that permits the measurement of
telomere elongation of individual telomeres in S. cerevisiae
(Teixeira et al., 2004). Using this assay, he showed that the
number of nucleotides added by telomerase in any single cell
cycle is independent of telomere length and that telomerase
preferentially elongates shorter telomeres, observations con-
sistent with genetic experiments in mice (Hemann et al., 2001).
Kathy Collins (University of California, Berkeley) showed that
the assembly of the telomerase holoenzyme requires several
RNA processing steps (Fu and Collins, 2003). Significantly,
defects in RNA processing lead to deficient telomerase assem-
bly and activity (Mitchell et al., 1999) that contribute directly to
the pathogenesis of dyskeratosis congenita, an inherited disor-
der characterized by aplastic anemia, skin and nail changes,
and cancer susceptibility (Wong and Collins, 2003).
In addition, Maria Blasco (Spanish National Cancer Center,
Madrid) showed that the state of telomeric chromatin affects
telomere length regulation. Mice lacking the Suv39 histone
methyltransferases harbor telomeres that are longer than in
control littermates. This change in length correlates with telom-
eric chromatin that is less heterochromatic (Garcia-Cao et al.,
2004). Woodring Wright (University of Texas, Southwestern,
Dallas) also showed that areas of subtelomeric DNA exist that
are resistant to nuclease digestion (Steinert et al., 2004).These
X regions correlate with telomere length. Since recent ultra-
structural studies demonstrate that telomeres form T loops that
contain higher order chromatin structures (Nikitina and
Woodcock, 2004), these studies suggest that further progress
in understanding how telomere maintenance is achieved will
require a deeper understanding of the proteins and interactions
that control telomeric chromatin.
Taken together, these observations confirm the importance
of telomere maintenance and telomerase activation for cancer
development and underscore the potential utility of telomerase
inhibition therapy for cancer. Calvin Harley (Geron Corporation,
Menlo Park) presented an update of work on modified thio-
phosphoramidate oligonucleotide inhibitors of telomerase (Asai
et al., 2003), which appear to have little nonspecific toxicity. In
particular, he showed that GRN163L, a lipid-modified analog of
their lead modified oligonucleotide GRN163, is 3- to 10-fold
more effective than GRN163 in inhibiting telomerase activity in
cancer cell lines and tumor xenographs. Based on these pre-
clinical and additional pharmacokinetic studies, GRN163L is
moving toward clinical trials.
Although most human cancers use telomerase to maintain
telomeres, a significant minority use an alternative mechanism
(ALT) that involves recombination to stabilize telomere length
(Reddel, 2003). Roger Reddel (Children’s Medical Research
Institute, Sydney) presented compelling evidence that the spe-
cialized nuclear structure found in ALT cells that consists of
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telomeric chromatin within PML nuclear domains, called the
ALT-associated PML body (Yeager et al., 1999), correlates with
ALT activity. He showed that these ALT-associated PML bodies
are easily detectable in paraffin-embedded tissues and can be
used to detect ALT cells in glioblastoma multiforme, where the
presence of such bodies predicts a better prognosis (Hakin-
Smith et al., 2003), and in many soft tissue sarcomas and
osteosarcomas, where tumors that exhibit the ALT phenotype
have outcomes similar to those of telomerase-expressing
tumors. Thus, although further work will undoubtedly identify
new targets amenable for use as cancer diagnostics or thera-
peutics, these efforts are important first steps.
The roles of ARF and p53 in senescence, apoptosis, and
transformation
The p53 tumor suppressor protein plays an important role in
limiting cancer development (Levine, 1997). Up to half of all
human cancers show evidence of inactivating p53 mutations,
and many of the remainder harbor mutations or alterations of
proteins that regulate p53 or that are effectors of p53 function
(Hofseth et al., 2004). Moreover, several DNA tumor viruses
encode proteins (the simian virus 40 large T antigen, human
papillomavirus E6, and adenovirus E1B proteins) that inactivate
p53 and are required for cell transformation in permissive hosts
(Levine, 1990). Experimentally, mice lacking p53 show remark-
able tumor susceptibility, while mice heterozygous for p53 also
readily form tumors in which the remaining allele shows loss of
heterozygosity (Donehower et al., 1992; Jacks et al., 1994). In
sum, these observations strongly implicate inactivation of the
p53 pathway as an essential step in malignant transformation.
The p53 pathway responds to many different stimuli, includ-
ing DNA damage, telomere dysfunction, oncogene activation,
and hypoxia, by inducing either cell cycle arrest or apoptosis
(Slee et al., 2004). As such, p53 acts as an important sensor to
protect cells from genotoxic damage. Normal cells express low
levels of relatively unstable p53; however, after exposure to
genotoxic stimuli, p53 undergoes several posttranslational mod-
ifications (Slee et al., 2004). As a consequence, p53 is activated
and stabilized and can serve as a transcription factor that regu-
lates the expression of genes critical for apoptosis or cell cycle
arrest (Levine, 1997). This framework begins to explain the
importance of p53 in restricting malignant transformation, while
recent work has begun to elucidate the molecular details of how
this pathway is regulated.
MDM2 serves as an important regulator of p53 function.
MDM2 binds p53 and targets it for degradation. MDM2 is itself
regulated by ARF, one of two tumor suppressor gene proteins
encoded by the INK4A-ARF locus (Sherr, 2001). By antagoniz-
ing MDM2, ARF promotes p53 stabilization and induces cell
cycle arrest or apoptosis. Mice lacking the ARF gene but retain-
ing the other INK4A tumor suppressor gene, p16INK4A, sponta-
neously develop tumors and are highly susceptible to challenge
by chemical carcinogens and oncogenes (Kamijo et al., 1997).
Moreover, ARF induction acts as a key step in the stabilization
of p53 by oncogenes such as RAS and Myc (Zindy et al., 1998).
Charles Sherr (Howard Hughes Medical Institute at St. Jude
Children’s Research Hospital, Memphis) described recent
observations from his laboratory that have begun to elucidate
how ARF itself is regulated. Using mice in which the gene
encoding the green fluorescent protein (GFP) was substituted
for ARF genomic coding sequences, his group has found that
the ARF promoter is tightly repressed in most tissues. Only
ectopic retrolental masses and tumors that form in ARF null
mice show evidence of GFP expression, implicating ARF activa-
tion as an rate-limiting inhibitory step in the development of
such lesions (Zindy et al., 2003). In addition, several other ARF
binding partners have recently been described. One of these
proteins, nucleophosmin/B23, appears to play a critical role in
ARF stability and its function as a tumor suppressor protein
(Bertwistle et al., 2004). ARF protein turnover is also regulated
through its N-terminal ubiquitination (Kuo et al., 2004).This pro-
vides a rare example of a naturally occurring lysine-less protein
whose degradation is regulated by the ubiquitin-proteasome
pathway.
In addition to interactions with ARF and MDM2, recent work
suggests that several other interactions and modifications also
play important roles in regulating p53 function and provide
insight into the mechanisms by which particular p53 effector
mechanisms are activated. David Dornan (Genentech, South
San Francisco) showed that the human homolog of the
Arabidopsis ubiquitin ligase, COP-1, binds p53 (Dornan et al.,
2004). Suppression of COP-1 in U2OS osteosarcoma cells by
RNA interference increases p53 levels and enhances apoptosis
induced by ionizing radiation. Moreover, Melissa Jack and
Patrick Lee (University of Calgary Health Sciences Center,
Calgary) showed that DNA-PK and Chk2 independently and
sequentially phosphorylate a latent fraction of p53 (Jack et al.,
2004). Xin Lu (Ludwig Institute for Cancer Research, London)
described new insights into the apoptotic-stimulating proteins of
p53 (ASPP) family. The ASPP family members bind the DNA
binding domain of p53 and specifically upregulate the expres-
sion of p53-dependent apoptotic genes, such as Bax and PIG3,
in part by increasing the occupancy of p53 at certain promoters
(Samuels-Lev et al., 2001). While ASPP1 and ASPP2 both acti-
vate transcription of p53-dependent genes involved in apopto-
sis, a third ASPP family member, iASPP, antagonizes this
activation (Bergamaschi et al., 2003). Consistent with this func-
tion, expression of iASPP, similar to dominantly interfering
mutants of p53, cooperates with several oncogenes to trans-
form primary rat fibroblasts, and overexpression of iASPP has
been reported in some human cancers (Bergamaschi et al.,
2003).
The activation and stabilization of p53 leads to both apopto-
sis and cell cycle arrest. Thus, like telomere shortening, p53
controls different cell fates under different conditions. Over the
past several years, many downstream regulators of p53 have
been identified, and recent work has begun to identify the para-
meters and mechanisms that control these effector mecha-
nisms. In particular, many proapoptotic and antiproliferative
genes are transactivated by p53. Moreover, the p53 family
members p63 and p73 also appear to play roles in p53-depen-
dent apoptosis (Flores et al., 2002). However, evidence also
exists that suggests that p53 induces apoptosis in a transcrip-
tion-independent manner. Kevin Ryan (Beatson Institute for
Cancer Research) described recent work investigating these
transcription-independent functions of p53. Using a series of
p53 truncation mutants, his laboratory showed that a 37 amino
acid portion of p53 unable to transactivate several p53 tran-
scriptional targets suffices to induce apoptosis when expressed
in human cancer cell lines, at least in part, by altering the inter-
action of ASPP family members with the p53 family members
p63 and p73. Although these studies, together with a large body
of literature, confirm the large number and complexity of interac-
tions that regulate p53, such approaches nonetheless offer
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important clues to understanding p53 function in specific cir-
cumstances.
Moreover, these studies provide the foundation for potential
strategies targeting the p53 pathway for therapeutic interven-
tion. One assumption inherent in this approach is that restoring
p53 function will provide primarily a tumor protective benefit.
However, recent work has also implicated altered p53 function
as a contributor to aging, suggesting that modulating the p53
pathway may affect more than just tumor resistance.To address
these issues, Manuel Serrano’s laboratory (Spanish National
Cancer Center) has created transgenic mice expressing multi-
ple copies of a large region of chromosomal region surrounding
the p53 locus in order to assess the effect of superphysiological
p53 (Garcia-Cao et al., 2002). Such mice express superphysio-
logical levels of p53 upon exposure to ionizing radiation and
show an enhanced ability to respond to radiation as measured
by radiation-induced thymocyte apoptosis. In addition, such
mice exhibit increased resistance to various stimuli that induce
tumor formation, yet show normal longevity and phenotypes
associated with aging. Although these studies appear to disso-
ciate a potential role for senescence in aging, further detailed
studies with these mice, as well as mice expressing estrogen
receptor-p53 fusion genes to permit temporal regulation of 
p53 expression (Gerard Evan, University of California, San
Francisco), will undoubtedly provide important insights into the
relationship of tumor suppression and aging.
Roles of physiological responses to environmental stress-
es to cancer development
Throughout life, the cells and tissues that comprise our bodies
are inundated with environmental agents that have the potential
to damage cells and promote cancer development. In particular,
DNA damage induced by carcinogens, ionizing radiation, or
other genotoxic agents presents a potent force in cancer initia-
tion. Indeed, the use of cytotoxic agents to treat patients with
cancer leads to a dramatically higher lifelong risk of second can-
cers. Cells have evolved various protective mechanisms to
sense and to protect the organism from these genotoxic insults,
and although the p53 and telomere maintenance pathways par-
ticipate in some of these responses, other pathways also play
critical roles in sensing DNA damage and changes in the envi-
ronment. Recent work from many laboratories has provided
important new information about the mechanisms by which
cells sense and respond to DNA damage.
Michael Kastan (St. Jude Children’s Research Hospital,
Memphis) offered recent insights into the early events that lead
to the activation of the ATM kinase after induction of DNA dam-
age by ionizing radiation. The ATM kinase plays a central role in
the immediate response to DNA double-strand breaks and initi-
ates the DNA damage response pathway in part through its
ability to phosphorylate several effector mechanisms (Bakkenist
and Kastan, 2004). Almost immediately after ionizing radiation,
ATM itself becomes autophosphorylated at serine 1981, and
this autophosphorylation is essential for ATM function
(Bakkenist and Kastan, 2003). Interestingly, the Kastan labora-
tory has found that alterations in chromatin structure induced by
treatments such as exposure to hypotonic saline, trichostatin, A
or chloroquinine stimulates ATM autophosphorylation in the
absence of DNA double-stranded breaks (Bakkenist and
Kastan, 2003). These findings agree with recent work in mice
lacking one or both copies of the histone H2AX, which show
enhanced genomic instability and susceptibility to tumor forma-
tion (Bassing et al., 2003; Celeste et al., 2003), and together
suggest that specific chromatin alterations are part of the sen-
sor mechanisms for DNA damage.
Once activated, ATM initiates several effector pathways,
including both S and G2 cell cycle checkpoints, the DNA dam-
age repair machinery, and the p53 pathway. Recent work from
several laboratories is now beginning to provide some under-
standing of how each of these specific effector pathways oper-
ates. Nick La Thangue (University of Glasgow, Glasgow)
described the role of the ATM kinase target Strap (Demonacos
et al., 2001). Phosphorylation of Strap by ATM alters its subcel-
lular localization and facilitates the repair of DNA damage in
part through its effects on the acetylation of p53 (Demonacos et
al., 2004). Consistent with these observations, Strap remains
localized in the cytoplasm in cells derived from patients with
ataxia telangiectasia. ATM activation also leads to activation of
the Chk1 and Chk2 kinases, which play important roles in both
DNA damage responses and replication control. Using the
DT40 chicken B cell lymphoma model, David Gillespie (Beatson
Institute for Cancer Research, Glasgow) showed that unlike fis-
sion yeast, Chk1 plays a dominant role in stabilizing stalled
replication forks and maintaining a mitotic checkpoint in verte-
brates (Zachos et al., 2003). Michael Kastan also showed that
phosphorylation of the SMC-1 kinase by ATM plays a critical
role in mediating radiosensitivity and chromosomal instability
(Kitagawa et al., 2004). Taken together, these studies begin to
provide important clues to understanding how cells respond to
DNA damage and other stresses.
Although many tumor suppressor pathways regulate cell
proliferation and apoptosis in response to stresses induced by
genotoxic agents and oncogene activation, emerging evidence
exists that suggests that mutations that disrupt homeostatic
mechanisms responsible for regulating nutrient metabolism and
growth also contribute to cancer development. In particular, the
mechanisms that control cell growth are distinct from, although
interconnected with, those that regulate cell proliferation. Iswar
Hariharan (University of California, Berkeley) described a large-
scale genetic screen in Drosophila to look for genes that control
cell growth. By looking for mutants that disrupt eye size regula-
tion, his laboratory has found several genes that play important
roles in growth regulation. For example, the Drosophila
homologs of the tuberosclerosis genes Tsc1 and Tsc2 control
cell size likely through their effects on the TOR pathway (Tapon
et al., 2001). Since alterations in Tsc and PTEN associate with
several types of human cancer (Kwiatkowski, 2003), these find-
ings implicate the mechanisms that control cell growth control
as important contributors to the cancer phenotype. In addition,
archipelago, a F box/WD family member, affects cyclin E and
Myc levels, and the human ortholog hCDC4 is found mutated in
endometrial and colorectal cancers (Moberg et al., 2001, 2004).
Taken together, these observations suggest that further charac-
terization of the genes responsible for growth regulation will
yield critical insights into pathways that participate in cancer
development.
New tools and models
Much of our understanding of cancer derives from the study of
tumor specimens isolated from cancer patients. Over the past
decade, dramatic improvements in technologies for sequencing
and identifying alterations in the cancer genome have permitted
detailed study of the cancer genome and suggest that a com-
plete catalog of cancer alterations may soon be possible. In par-
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allel to these advances, increasingly sophisticated and relevant
human and murine models are now available for the identifica-
tion and characterization of the critical mutations that program
specific cancer phenotypes.
Robert Weinberg (Whitehead Institute for Biomedical
Research, Cambridge) delivered the conference keynote lec-
ture and described recent progress in using cell-based models
to understand carcinoma development. In particular, he showed
how understanding the role of telomerase expression in cell
immortalization has facilitated the development of human can-
cer models, particularly epithelial cancer models (Hahn and
Weinberg, 2002). Recent work suggests that such experimental
models, when cultured under appropriate conditions and placed
orthotopically into murine hosts, permit the development of
tumors with differentiation patterns reminiscent of human
epithelial cancers (Kuperwasser et al., 2004). For example,
Gordon Peters (Cancer Research UK London Research
Institute, London) showed that this type of experimental scheme
permits one to study pathways implicated in cancer pathogene-
sis. Specifically, using primary human cells derived from
patients with inherited predisposition to melanoma due to muta-
tions in the INK4A-ARF locus, he showed that loss of p16INK4A
but not ARF function cooperates with expression of Myc, Ras,
and telomerase to transform some types of human cells, and
that tumorigenicity is enhanced with the concomitant loss of
p53 function (Drayton et al., 2003). These studies, together with
those from other laboratories using various combinations of
introduced genes and cell types, promise to provide further
insights into which specific combinations of genetic alterations
cooperate to permit tumor formation.
While such studies permit the investigation and characteri-
zation of cancer-associated alterations that permit tumor forma-
tion, in most cases, these transformed human cells fail to
recapitulate the capacity of cancers to invade surrounding tis-
sues and metastasize to distant sites. Addressing this important
issue, Robert Weinberg described the identification of the Twist
transcription factor as one key factor that regulates invasion and
metastasis (Yang et al., 2004). Using a series of murine cancer
cell lines derived from a primary mammary tumor that exhibit
differential abilities to invade and metastasize, his group used
transcriptional profiling to identify genes whose expression cor-
related with metastatic behavior. One of these genes, Twist,
when overexpressed in nonmetastatic cell lines, induced
metastasis, while suppression of Twist expression in metastatic
cell lines inhibited metastatic growths. Correlating with these
findings, Twist is overexpressed in a subset of metastatic breast
cancers. Although other factors certainly contribute to the com-
plex phenotypes associated with invasion and metastasis,
these studies begin to provide insight into the molecules impor-
tant for these cancer phenotypes.
Until recently, cancer researchers have used overexpres-
sion of oncogenes or dominantly interfering mutants to create
cell-based models of cancer.The demonstration that RNA inter-
ference operates efficiently in mammalian cells now provides an
important tool to the study of specific molecules in transforma-
tion (Elbashir et al., 2001). Indeed, Agami and his colleagues
have used retroviral delivery of short hairpin RNA (shRNA) mol-
ecules to confirm that loss of RB and p53 function cooperates to
transform human cells (Voorhoeve and Agami, 2003). In addi-
tion to using shRNA technology to study specific molecules and
their interactions, large collections of RNA interference
reagents promise to provide genetic tools to identify molecules
important for cancer development and to facilitate genotype-to-
phenotype connections. Rene Bernards (Netherlands Cancer
Institute, Amsterdam) described a series of experiments using
an evolving library of shRNA reagents. Using a pooled library
harboring siRNAs for each member of the family of deubiquiti-
nating (DUB) enzymes, he showed that suppression of a single
DUB, the familial cylindromatosis tumor suppressor (CYLD),
enhances the transcriptional activity of NF-κB (Brummelkamp
et al., 2003). Followup molecular and cellular studies confirmed
that CYLD binds the IKK-γ subunit of IKB kinase complex and
regulates the ubiquitination of TRAF2, thereby inhibiting apop-
tosis. Since aspirin derivatives inhibit NF-κB activity, these stud-
ies help not only elucidate the molecular mechanism underlying
this rare disorder, but also provide a rational therapeutic treat-
ment strategy. Using a larger library of shRNAs targeting nearly
8000 genes, Bernards also showed how such libraries will be
useful for large-scale screening of phenotypes such as modula-
tors of p53 function (Berns et al., 2004).
While such cell-based approaches certainly provide useful
experimental systems that permit the rapid genetic and bio-
chemical dissection of cancer pathways, the next generation of
murine models of cancer promises to allow the detailed study of
cancer physiology. Indeed, while traditional gene targeting of
tumor suppressor genes in mice has confirmed roles of onco-
gene activation and tumor suppressor loss in cancer develop-
ment, more sophisticated models that permit temporal, tissue-
and cell-specific gene targeting in adult animals will facilitate the
creation of experimental models that increasingly recapitulate
the changes that occur in human cancer development. Tyler
Jacks (Massachusetts Institute of Technology, Cambridge)
described several new murine cancer models derived by intro-
ducing latent alleles of oncogenic K-RAS into the murine
genome. One version of this type of allele spontaneously acti-
vates in a subset of cells and induces non-small cell lung cancer
with high penetrance (Johnson et al., 2001). A variation of this
strategy that permits the activation of this allele through aden-
oviral delivery of the Cre recombinase allowed his group to con-
trol the multiplicity and timing of lung cancer development and
identify a specific cell type, one that has characteristics of both
the Clara cells and type II pneumocytes as the target for trans-
formation in the lung (Jackson et al., 2001). Other groups have
used a similar strategy to produce experimental models of pan-
creatic cancer that recapitulate many of the phenotypes of the
human disease (Aguirre et al., 2003; Hingorani et al., 2003).
Moreover, several laboratories have developed compound
transgenic mice lacking combinations of specific tumor sup-
pressor genes in specific tissues.These mice provide important
clues to the tissue type specificity of gene mutation. in particular
cancers. Anton Berns (Netherlands Cancer Institute,
Amsterdam) showed that conditional loss of both p53 and RB in
the murine lung leads to neuroendocrine tumors of the lung
(Meuwissen et al., 2003). Such tumors resemble human small
cell lung cancers immunohistochemically and, like human small
cell lung cancers, demonstrate a high capacity to form metasta-
tic extrapulmonary tumors.Taken together with the K-RAS stud-
ies, these observations suggest that particular cell types within
the same tissue possess different responses to gene mutation.
Moreover, in prior work, the Berns laboratory showed that a
specific combination of gene mutation in the INK4A-ARF locus,
namely complete loss of p16INK4A and heterozygous loss of ARF,
conferred susceptibility to melanoma and other tumors, sug-
gesting that haploinsufficiency at some tumor suppressor loci
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may also play a role in the development of specific human can-
cers (Krimpenfort et al., 2001).
While these experimental models focus on the events nec-
essary to initiate tumor development, an equally important
question is what events are necessary to permit tumor mainte-
nance. Gerard Evan (University of California, San Francisco)
described work from his laboratory using transgenic mice har-
boring an estrogen receptor-c-Myc fusion gene in pancreatic β
cells or the epidermis (Pelengaris et al., 2002; Flores et al.,
2004). Activation of Myc by the addition of tamoxifen leads to
massive β cell apoptosis that is abrogated by simultaneous
expression of Bcl-XL (Pelengaris et al., 2002). In the presence
of Bcl-XL, activation of Myc induces angiogenic, invasive
tumors that are dependent upon Myc expression. Inactivation of
Myc by tamoxifen withdrawal leads to tumor regression accom-
panied by vascular degeneration and apoptosis. These findings
confirm that continued Myc expression is necessary for tumor
maintenance, and that tumor cells survive on the cusp of unreg-
ulated proliferation and apoptosis. Moreover, together with stud-
ies from other laboratories (Chin et al., 1999b; Jain et al., 2002),
these experimental models provide important systems to study
the role of the oncogenes in programming particular cancer
phenotypes.
Thus, although focused on the roles of senescence, cell
cycle regulation, and apoptosis in cancer, this conference show-
cased a broad cross-section of cancer research and provided
an opportunity for the attendees to integrate and discuss obser-
vations drawn from cell- and animal-based models, genetic and
biochemical approaches, and the study of experimental models
and human tumor specimens. This conference reinforced the
notion that it is now increasingly possible to integrate these dis-
parate approaches to elucidate a clearer picture of the molecu-
lar basis of cancer. While much further work remains to fully
understand cancer initiation, maintenance, and progression,
this conference certainly provided an excellent venue to
exchange ideas. Moreover, although not focused on cancer
therapeutics, many of the presentations provided new hypothe-
ses and frameworks that may lead to new targeted, antineoplas-
tic therapies.
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